Monday, November 06, 2023
Researchers at the University of Sheffield and Nottingham Trent University are in the process of developing the world's inaugural lateral flow test geared towards detecting recurring aggressive brain tumors. This groundbreaking diagnostic tool, resembling the tests used during the Covid-19 pandemic, is designed to be user-friendly and can be utilized by patients in the comfort of their homes. The project is financially supported by the Medical Research Council and primarily aims to address the issue of aggressive recurring brain tumors, which currently account for nearly 200,000 global fatalities each year.
While the recurrence of tumors following initial treatment is a common challenge for patients, the unpredictability of this recurrence timing makes early detection a daunting task, leading to unfavorable outcomes.
The researchers are optimistic that this novel technology could greatly enhance the quality of life for countless individuals worldwide. It also has the potential to reduce the reliance on expensive MRI scans and offer a cost-effective alternative to certain clinic visits.
The technology, involving a straightforward finger-prick test, is focused on the development of lateral flow tests that can identify specific tumor-related molecules in the blood, thus offering an early indication of tumor recurrence.
At present, the research team is in the process of developing prototype lateral flow tests in the lab, with subsequent plans for clinical validation. The primary target for this technology is the detection of aggressive brain tumors such as glioblastoma (GBM), which is the most malignant form of brain tumor.
Source: sheffield.ac.uk
